{"analyses":[{"ciLowerLimit":"2.535","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"32.265","groupDescription":"The incidence of overall platelet response was compared by the Cochran-Mantel-Haenszel test stratified by the baseline age group. The Mantel-Haenszel common odds ratio (romiplostim vs placebo) was estimated along with its 95% confidence interval.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","paramType":"Odds Ratio (OR)","paramValue":"9.0443","statisticalComment":"P-value from Cochran-Mantel-Haenszel test stratified by baseline age group.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"43.7","value":"20.0"},{"groupId":"OG001","lowerLimit":"55.4","upperLimit":"84.3","value":"71.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"Overall platelet response is defined as either a durable platelet response or transient platelet response.\n\nDurable platelet response was defined as weekly platelet count ≥ 50 x 10\\^9/L for 6 or more times during week 18 to week 25 measurements. Participants may not have had a weekly response within 4 weeks after receiving any rescue medication.\n\nTransient platelet response was defined as weekly platelet count ≥ 50 x 10\\^9/L for 4 or more times during week 2 to week 25 measurements but without durable platelet response. Participants may not have had a weekly response within 4 weeks after receiving any rescue medications.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received weekly subcutaneous placebo for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\\^9/L.","id":"OG001","title":"Romiplostim"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"Week 2 to week 25","title":"Percentage of Participants With an Overall Platelet Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}